WallStSmart

Medtronic PLC (MDT)vsMarvell Technology Group Ltd (MRVL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 307% more annual revenue ($35.48B vs $8.72B). MRVL leads profitability with a 29.0% profit margin vs 13.0%. MDT appears more attractively valued with a PEG of 1.29. MDT earns a higher WallStSmart Score of 61/100 (C+).

MDT

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.5Value: 6.0Quality: 4.8
Piotroski: 2/9

MRVL

Buy

55

out of 100

Grade: C

Growth: 6.0Profit: 7.0Value: 3.7Quality: 8.0
Piotroski: 5/9Altman Z: 1.90
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$89.60

Current Price

$81.67

$7.93 discount

UndervaluedFair: $89.60Overvalued

Intrinsic value data unavailable for MRVL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$94.69B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

MRVL4 strengths · Avg: 9.0/10
Market CapQuality
$264.11B10/10

Mega-cap, among the largest globally

Profit MarginProfitability
29.0%9/10

Keeps 29 of every $100 in revenue as profit

Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
27.6%8/10

Revenue surging 27.6% year-over-year

Areas to Watch

MDT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

MRVL4 concerns · Avg: 3.5/10
PEG RatioValuation
1.644/10

Expensive relative to growth rate

Price/BookValuation
18.7x4/10

Trading at 18.7x book value

Altman Z-ScoreHealth
1.904/10

Grey zone — moderate risk

P/E RatioValuation
104.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : MRVL

The strongest argument for MRVL centers on Market Cap, Profit Margin, Debt/Equity. Profitability is solid with margins at 29.0% and operating margin at 14.5%. Revenue growth of 27.6% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are Piotroski F-Score, EPS Growth.

Bear Case : MRVL

The primary concerns for MRVL are PEG Ratio, Price/Book, Altman Z-Score. A P/E of 104.0x leaves little room for execution misses.

Key Dynamics to Monitor

MDT profiles as a value stock while MRVL is a growth play — different risk/reward profiles.

MRVL carries more volatility with a beta of 2.25 — expect wider price swings.

MRVL is growing revenue faster at 27.6% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (61/100 vs 55/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Marvell Technology Group Ltd

TECHNOLOGY · SEMICONDUCTORS · USA

Marvell Technology, Inc. designs, develops, and sells analog, mixed-signal, digital signal processing, and integrated and independent integrated circuits. The company is headquartered in Wilmington, Delaware.

Visit Website →

Want to dig deeper into these stocks?